New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
09:55 EDTBTX, CUR, ASTM, STEM, GERN, OSIRSupreme Court turns down appeal over stem cell research, SCOTUSblog says
The Supreme Court turned down an appeal by scientists seeking to stop all studies on embryonic stem cells, according to SCOTUSblog. The Fly notes that companies engaged in the research, development, and commercialization of stem cell therapies include StemCells (STEM), Neuralstem (CUR), Aastrom Biosciences (ASTM) and Osiris Therapeutics (OSIR). Also, earlier this morning, BioTime (BTX) entered into an agreement to acquire the intellectual property, including patents and patent applications, and other assets related to Geron's (GERN) human embryonic stem cell programs. Reference Link
News For STEM;CUR;OSIR;ASTM;BTX;GERN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
09:58 EDTSTEMOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Allison Transmission (ALSN) initiated with a Buy at Stifel... Avago (AVGO) initiated with a Buy at Mizuho... Blackstone (BX) initiated with a Positive at Susquehanna... Cellectis (CLLS) initiated with an Outperform at Oppenheimer... Cypress Semiconductor (CY) initiated with a Buy at Mizuho... Esperion (ESPR) initiated with a Sell at Chardan... H&R Block (HRB) initiated with an Overweight at Piper Jaffray... Horizon Pharma (HZNP) initiated with an Outperform at Leerink... M/A-COM (MTSI) initiated with a Buy at Goldman... Meritor (MTOR) initiated with a Hold at Stifel... Micron (MU) initiated with a Buy at Mizuho... Monster Worldwide (MWW) initiated with a Neutral at Piper Jaffray... NXP Semiconductors (NXPI) initiated with a Buy at Mizuho... National Storage (NSA) initiated with a Sector Weight at KeyBanc... ON Semiconductor (ON) initiated with a Buy at Mizuho... Qorvo (QRVO) initiated with a Buy at Goldman... SanDisk (SNDK) initiated with a Neutral at Mizuho... Sharps Compliance (SMED) initiated with a Buy at Stifel... Skyworks (SWKS) initiated with a Buy at Mizuho... StemCells (STEM) initiated with a Buy at Cantor... Synaptics (SYNA) initiated with a Buy at Mizuho... Synergy Pharmaceuticals (SGYP) initiated with a Buy at Canaccord... Texas Instruments (TXN) initiated with a Neutral at Mizuho... TriNet (TNET) initiated with a Neutral at Piper Jaffray... Vascular Biogenics (VBLT) initiated with a Buy at Roth Capital... Verifone (PAY) initiated with an Outperform at Imperial Capital... uniQure (QURE) initiated with an Outperform at Oppenheimer.
May 21, 2015
18:49 EDTSTEMOn The Fly: After Hours Movers
UP AFTER EARNINGS: Hewlett-Packard (HPQ), up 1%. ALSO HIGHER: Autobytel (ABTL), up 14.1% after acquiring Dealix Corporation and Autotegrity from CDK Global (CDK) for $25M and raising fiscal 2015 guidance... StemCells (STEM), up 2.5% after being initiated with a Buy at Cantor... PTC Therapeutics (PTCT), up 2.3% after a Benefit Assessment by Germany's Federal Joint Committee indicated that Translarna provided a benefit for ambulatory patients... CBOE Holdings (CBOE), up 1.6% after raising share repurchase authorization by $100M... Cypress Semiconductor (CY), up 1.2% after being initiated with a Buy at Mizuho. DOWN AFTER EARNINGS: Aeropostale (ARO), down 18.5%... Brocade (BRCD), down 2.1%... Marvell Technology (MRVL), down 2.9% after reporting quarterly results and departure of CFO. ALSO LOWER: Otonomy (OTIC), down 17.7% following report of Phase 2b topline data for OTO-104... Viggle (VGGL), down 18.8% after filing to sell common stock... CEL-SCI (CVM),down 2.7% after announcing a proposed offering of common stock and warrants.
16:41 EDTOSIROsiris evaluates the establishment of an international subsidiary
Osiris Therapeutics developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced that it is evaluating the establishment of an international, ex-U.S. subsidiary in recognition of its expanding research and commercial business operations. The company is currently evaluating different locations, including United Kingdom, Singapore and Switzerland.
16:05 EDTSTEMStemCells initiated with a Buy at Cantor
Target $2.
May 19, 2015
08:04 EDTBTXBioTime says positive interim results of blood-based cancer test to be presented
Subscribe for More Information
May 18, 2015
10:01 EDTSTEMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:12 EDTSTEMStemCells initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated StemCells with a Buy rating and $1 price target. The firm is encouraged by StemCells preliminary data from early trials of dry age-related macular degeneration and chronic spinal cord injuries.
May 14, 2015
08:40 EDTSTEMStemCells announces positive top-line results of HuCNS-SC Phase I/II study
StemCells announced that Dr. Armin Curt, principal investigator, will present a summary of the safety and preliminary efficacy data from the Phase I/II study investigating Human Central Nervous System Stem Cell, or HuCNS-SC, intramedullary transplantation in thoracic spinal cord injury. The summary will be presented today at 10:15 a.m. EDT at the 4th Joint International Spinal Cord Society, or ISCoS, and American Spinal Injury Association, or ASIA, meeting being held in Montreal, Canada. The abstract was selected as one of the top six platform submissions for the conference. The international, open-label, Phase I/II trial evaluated both safety and preliminary efficacy of StemCells, Inc.'s proprietary HuCNS-SC human neural stem cells as a treatment for chronic spinal cord injury. The trial enrolled twelve patients who had suffered injury to the thoracic cord and were in the early chronic stage of recovery. The severity of spinal cord trauma is classified by the ASIA Impairment Scale, or AIS, according to the degree of sensory and motor loss. Patients classified as AIS A, the most severe injury, have lost both sensory and motor function below the level of injury. AIS B patients are considered less severely injured because, although they also have no motor function below the level of injury, some limited sensory function is maintained. The protocol was specifically designed to test safety and preliminary efficacy across this spectrum of injury severity, and ultimately the trial transplanted seven AIS A and five AIS B patients.
08:03 EDTBTXBioTime sees OncoCyte funding sufficient for operations into early 2016
BioTime and its subsidiary OncoCyte Corporation announced that OncoCyte has received a new round of financing to fund further development and commercialization activities for its cancer diagnostic products. With completion of the financing, which included a cash investment of $3.3M and conversion of $3.3M of existing debt into equity, OncoCyte has approximately $7M in cash and marketable securities, which should be sufficient to fund current operations into early 2016, the company stated.
May 13, 2015
08:04 EDTBTXBioTime unit awarded $1.6M grand from Israel's OCS
BioTime and its subsidiary Cell Cure Neurosciences announced that Cell Cure has been awarded a grant for 2015 of approximately $1.61M from Israelís Office of the Chief Scientist to help finance the development of OpRegen, a cell-based therapeutic product that consists of animal product-free retinal pigment epithelial cells with high purity and potency. Cell Cure is now enrolling patients at Hadassah University Medical Center in Jerusalem, Israel, in a clinical Phase I/IIa dose-escalation study evaluating the safety and efficacy of OpRegen for geographic atrophy, the severe stage of the dry form of age-related macular degeneration. The Phase I/IIa clinical trial was opened in February 2015 following regulatory clearance from the U.S. FDA and the Israeli Ministry of Health. The trial consists of four cohorts and will evaluate three different dose regimens. Cell Cure expects to report interim data from the cohorts in the coming months.
May 12, 2015
09:38 EDTBTXBioTime management to meet with Oppenheimer
Meetings to be held in New York on May 14 and in Boston on May 15 hosted by Oppenheimer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use